Evogene (NASDAQ:EVGN) Releases Earnings Results, Misses Estimates By $0.33 EPS

Evogene (NASDAQ:EVGN) posted its earnings results on Wednesday. The biotechnology company reported ($0.60) EPS for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.33), FiscalAI reports. The company had revenue of $0.33 million during the quarter, compared to analysts’ expectations of $0.35 million. Evogene had a negative net margin of 638.12% and a negative return on equity of 142.00%.

Here are the key takeaways from Evogene’s conference call:

• Evogene said it is sharpening its strategy around ChemPass AI and two core markets: small-molecule pharma and next-generation ag chemicals, with a business model built on partnerships and internally funded pipeline development.
• The company highlighted continued momentum in AI platform development, including a second collaboration with Google to build AI agents that could extract scientific insights and generate proprietary datasets for better molecule design.
• Evogene’s Pharma Division added three new collaborations in Q1, targeting inflammatory disease, demyelinating disorders, and chemotherapy resistance, which management said expands a growing small-molecule pipeline.
• In ag chemicals, AgPlenus and Bayer terminated their herbicide research collaboration after target biology issues limited further development, though management said the relationship remains constructive and future collaboration is possible.
• The internal Septoria fungicide program showed strong progress: iterative AI-guided screening materially improved hit rates, and the company now has high expectations for advancing the lead set.
• Evogene ended Q1 with about $13.1 million in cash and a $5.9 million net loss, while revenues fell sharply year over year to about $0.3 million due mainly to lower Casterra seed sales.

Evogene Price Performance

NASDAQ EVGN opened at $0.69 on Friday. The firm’s fifty day moving average price is $0.79 and its 200 day moving average price is $0.96. The company has a market capitalization of $6.05 million, a price-to-earnings ratio of -0.50 and a beta of 1.39. Evogene has a 12 month low of $0.66 and a 12 month high of $2.42.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of EVGN. Citadel Advisors LLC grew its position in shares of Evogene by 169.4% in the 3rd quarter. Citadel Advisors LLC now owns 57,575 shares of the biotechnology company’s stock valued at $66,000 after buying an additional 36,206 shares during the last quarter. XTX Topco Ltd purchased a new position in shares of Evogene in the 4th quarter valued at $25,000. Finally, Jane Street Group LLC grew its position in shares of Evogene by 58.0% in the 1st quarter. Jane Street Group LLC now owns 33,732 shares of the biotechnology company’s stock valued at $42,000 after buying an additional 12,387 shares during the last quarter. 10.40% of the stock is owned by hedge funds and other institutional investors.

About Evogene

Evogene Ltd. is a biotechnology company specializing in the use of computational and predictive biology technologies to design and develop novel products for agriculture and human health. Founded in 2002 and headquartered in Rehovot, Israel, the company has built a proprietary computational platform that integrates genomics, machine learning and data analytics to identify gene targets and biological traits. Evogene’s platform serves as the backbone for its research and development efforts, enabling the discovery of enhanced crop traits, microbial solutions and microbiome-based diagnostics and therapeutics.

In the agricultural sector, Evogene applies its platform to improve crop performance across a range of parameters, including yield enhancement, stress tolerance and resistance to pests and pathogens.